The seasoned executive will support and further the biotech company’s cell therapeutics growth by facilitating company expansion, capitalization and strategic development.
DENVER–(BUSINESS WIRE)–$GLTI #biotech–Second paragraph, second sentence of release dated September 6, 2022, should read: Jim is a seasoned leader, and as Greyledge continues to accelerate efforts to scale our novel cellular therapeutics platform in domestic and international markets, he will be a vital asset to access additional growth capital and provide comprehensive strategic guidance,” said Dr. David Karli, founder and CEO of Greyledge. (instead of Jim is a seasoned leader and, as Greyledge continues to accelerate efforts to scale our novel cellular therapeutics platform in domestic and international markets. He will be a vital asset to access additional growth capital and provide comprehensive strategic guidance,” said Dr. David Karli, founder and CEO of Greyledge.)
The updated release reads:
JAMES JOHNSTON NAMED TO GREYLEDGE TECHNOLOGIES BOARD OF DIRECTORS
The seasoned executive will support and further the biotech company’s cell therapeutics growth by facilitating company expansion, capitalization and strategic development.
James Johnston, an innovative executive with extensive financial and strategic experience with global organizations, has joined the board of directors of Greyledge Technologies, Inc. (“Greyledge” or “the Company”). He has served as Chief of Corporate Development for Greyledge since last fall. His extensive network of contacts, diverse strategic abilities and extensive experience in investment banking and private equity will continue to facilitate the cell therapeutics company’s growth strategy, while maintaining its commitment to quality standards.
“Mr. Johnston has been an instrumental member of the Greyledge team in his role as Chief of Corporate Development and we are thrilled to appoint him to the board. Jim is a seasoned leader, and as Greyledge continues to accelerate efforts to scale our novel cellular therapeutics platform in domestic and international markets, he will be a vital asset to access additional growth capital and provide comprehensive strategic guidance,” said Dr. David Karli, founder and CEO of Greyledge.
Mr. Johnston has spent 22 years advising and investing in companies across a variety of industries. He brings expertise in financing, mergers and acquisitions, strategic execution and board level decision making. Jim was an investment banker at Goldman Sachs from 2000-2008 in Mergers and Acquisitions and Financial Sponsor Coverage. He joined Nexphase Capital Partners (FKA Moelis Capital Partners) in 2008 where he ultimately ran the Industrials Group as a Partner. In 2018, Mr. Johnston left Nexphase and founded Emerald Lake Advisors in order to focus his energy on investing and advising small entrepreneurial companies.
Mr. Johnston serves on the board of directors of the Red Fox Community School and as a board observer of Jame Rollform Products. He received a BS in Commerce with Distinction from the University of Virginia in 1991 and was commissioned as a Naval Officer through the ROTC program. After graduating Nuclear Power School and Prototype he served as a submarine officer and is a qualified Naval Nuclear Engineer. After his separation from the Navy, he received his MBA from Harvard Business School in 2000.
For more information regarding Greyledge and its biologic products and services, please email info@greyledgebiotech.com.
About Greyledge, Inc.
Founded in 2010 in Colorado, Greyledge is an industry-leading biotech company specializing in cell therapeutics produced from a patient’s own blood or bone marrow tissue. Greyledge has developed industry-leading quality control systems to process these biologic therapy products, used in treating common Orthopedic conditions. The Company is dedicated to maximizing product quality, safety, and reliability in a manner compliant with Federal regulations and ethical standards. The Company has refined its scientific technology, and since 2017, has been driven to achieve sustained profitability and scalability.
Forward-Looking Statements
This press release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors.
Contacts
Greyledge Technologies
D: (970) 236-8670, info@greyledgebiotech.com
